Labcorp (LH) Stock Price, News & Analysis

Company Overview

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services. Its diagnostics offerings include routine and specialty clinical tests, anatomic pathology, molecular and genomic testing, toxicology and companion diagnostics. On the drug development side, the company provides preclinical and clinical research services, central laboratory support, biomarker development, regulatory and commercialization services to pharmaceutical and biotechnology clients.

The company serves a wide range of customers including physicians, hospitals and health systems, biopharmaceutical companies, employers and public health agencies. Labcorp’s operations extend across the United States and into international markets through laboratory facilities, partnerships and service centers, enabling it to support clinical trials and diagnostic needs on a global scale.

Organized to combine diagnostic testing with drug development capabilities, Labcorp has developed integrated service offerings designed to streamline clinical development and accelerate the translation of laboratory findings into clinical and commercial outcomes. As a publicly traded company, it is positioned to leverage laboratory infrastructure, data analytics and scientific expertise to meet evolving needs in healthcare and life sciences.

Key Stats

• Today's Range: $251.06 to $255.63
• 50-Day Range: $250.30 to $275.10
• 52-Week Range: $239.75 to $293.72
• Volume: 528,755 shs
• Average Volume: 754,671 shs
• Market Capitalization: $20.74 billion
• P/E Ratio: 22.41
• Dividend Yield: 1.14%
• Price Target: $308.00
• Consensus Rating: Moderate Buy

Labcorp Stock Analysis - MarketRank™

Labcorp scored higher than 94% of companies evaluated by MarketBeat, and ranked 27th out of 851 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Labcorp has received a consensus rating of Moderate Buy. The company's average rating score is 2.73, and is based on no strong buy ratings, 8 buy ratings, 3 hold ratings, and no sell ratings.

Upside Potential

Labcorp has a consensus price target of $308.00, representing about 21.8% upside from its current price of $252.96.

Amount of Analyst Coverage

Labcorp has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 7.67%

Earnings Growth

Earnings for Labcorp are expected to grow by 7.67% in the coming year, from $17.99 to $19.37 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Labcorp is 22.41, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 42.78.

Price to Earnings Ratio vs. Sector

The P/E ratio of Labcorp is 22.41, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 17.54.

Price to Earnings Growth Ratio

Labcorp has a PEG Ratio of 1.79. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Labcorp has a P/B Ratio of 2.38. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.88% of the float of Labcorp has been sold short.

Short Interest Ratio / Days to Cover

Labcorp has a short interest ratio ("days to cover") of 4.12.

Change versus previous month

Short interest in Labcorp has recently decreased by 2.50%, indicating that investor sentiment is improving.

Dividend

• Score: 2.5 / 5
• Dividend Strength: Moderate

Dividend Yield

Labcorp pays a meaningful dividend of 1.13%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Labcorp does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Labcorp is 25.51%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Labcorp will have a dividend payout ratio of 14.87% next year. This indicates that Labcorp will be able to sustain or increase its dividend.

News and Social Media

• Score: 4.4 / 5
• News Sentiment: 0.99

News Sentiment

Labcorp has a news sentiment score of 0.99. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 10 news articles for Labcorp this week, compared to 5 articles on an average week.

Search Interest

15 people have searched for LH on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.

MarketBeat Follows

3 people have added Labcorp to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: 1.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Labcorp insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,524,961.00 in company stock.

Percentage Held by Insiders

0.84% of the stock of Labcorp is held by insiders.

Percentage Held by Institutions

95.94% of the stock of Labcorp is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Record date for 3/12 Dividend: 2/27/2026
• Ex-Dividend for 3/12 Dividend: 2/27/2026
• Dividend Payable: 3/12/2026
• Last Earnings: 4/30/2026
• Today: 5/19/2026
• AGM 2026: 5/21/2026
• Record date for 6/11 Dividend: 5/29/2026
• Ex-Dividend for 6/11 Dividend: 5/29/2026
• Dividend Payable: 6/11/2026
• Next Earnings (Estimated): 7/23/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Medical Services
• Sub-Industry: Health Care Services
• Current Symbol: NYSE:LH
• Previous Symbol: NYSE:LH?
• CIK: 920148
• Web: www.labcorp.com
• Phone: (336) 229-1127
• Fax: 336-513-4510
• Employees: 71,000
• Year Founded: 1995

Price Target and Rating

• Average Price Target for Labcorp: $308.00
• High Price Target: $334.00
• Low Price Target: $260.00
• Potential Upside/Downside: +21.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.73
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): $11.29
• Trailing P/E Ratio: 22.41
• Forward P/E Ratio: 14.06
• P/E Growth: 1.79
• Net Income: $876.50 million
• Net Margins: 6.66%
• Pretax Margin: 8.14%
• Return on Equity: 16.29%
• Return on Assets: 7.62%

Debt

• Debt-to-Equity Ratio: 0.68
• Current Ratio: 1.73
• Quick Ratio: 1.54

Sales & Book Value

• Annual Sales: $13.95 billion
• Price / Sales: 1.49
• Cash Flow: $24.58 per share
• Price / Cash Flow: 10.29
• Book Value: $106.45 per share
• Price / Book: 2.38

Miscellaneous

• Outstanding Shares: 82,000,000
• Free Float: 81,311,000
• Market Cap: $20.74 billion
• Optionable: Optionable
• Beta: 0.91